NAMI Pharma Marketing Blog Grassley

NAMI’s Pharma Funders – Serial Off-label Promoter Astrazeneca Tops the List
The National Alliance on Mental Illness (NAMI) until recently was reluctant to reveal the source of its funding. But thanks to Sen. Grassley we now can learn NAMI’s sources for Major Foundation and Corporate Support. Continue reading →

12-Year Old Denis Matez: Dead of Psych Drug Cocktail Rx by Psychiatrist

Twelve-year old, Denis Matez (weighing 68 lbs) is a human casualty of psychotropic drug "overmedication"– a notorious psychiatrist entrusted with the care of 800 Florida children in Florida foster care prescribed lethal mega doses for unapproved uses. Continue reading →

How to Stop Epidemic Antipsychotic Drug Prescribing

AHRP PROPOSAL:
Any FDA-approved drug, whose manufacturer has been found by a court of law or the Department of Justice–to have illegally marketed the drug by concealing risks or incidence of adverse effects, or making unsupported claims of clinical benefit–should be denied coverage by taxpayer funded insurance programs–including Medicaid, Medicare, VeteranstAffairs. Continue reading →

Scoop Interview: Vera Sharav — Peer Review “Fig Leaf”

1 April 2010   The Peer Review “Fig Leaf”: Vera Hassner Sharav  By SUZAN MAZUR   While the chief of the US National Institute of Mental Health this week stopped short of saying scientists are corrupt because of their ties to industry, as . . . Continue reading →

Rotavirus vaccine found contaminated–FDA Suspends Use of Rotarix

On March 22, 2010 the FDA recommended suspension in the use of GlaxoSMithKline’s Rotarix vaccine–to prevent rotavirus (diarrhea)–due to contamination with pig virus.  Rotarix, one of two vaccines licensed in the U.S , has already been given to about 1 million U.S. children along with 30 million worldwide.
Continue reading →

Specific Anticonvulsants Increase Suicide Risk

A large-scale Harvard meta-analysis published in the Journal of the American Medical Association, is the first ever to evaluate the relationship between different anticonvulsant drugs and the risk of suicide in for patients with diverse diagnoses: " the risk was derived from the specific drug that the patient was taking and not their underlying conditions." Continue reading →

In Medicine, the Power of No vs. Psychiatry’s Mass Overtreatment

Unlike patients in other fields of medicine, those  who are designated mentally ill–or even declared to be "at risk" for mental illness in the future–are at once stigmatized and suffer losss of their autonomy.
Continue reading →